Because ACE2 is present in tetraspanin-enriched microdomains, where it clusters with other glycoproteins, such as CD9, CD81, and TMPRSS2, we also established assays to define whether anti-IgM antibodies against any of these proteins were present in COVID-19 sera. The gene discussed is CD81; the disease is COVID-19.